SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Nevro Corp. (NVRO) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+419.2%).
- Analyst consensus target $30.32 (+419.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 45/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NVRO
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.53
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.06
Book Value / Share$0.00
Revenue / Share$11.01
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$30.32 (+419.2%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-2.54 |
$69.61M |
$-67.43M |
-96.9% |
| 2016 |
$-1.12 |
$228.5M |
$-31.78M |
-13.9% |
| 2017 |
$-1.25 |
$326.67M |
$-36.66M |
-11.2% |
| 2018 |
$-1.64 |
$387.29M |
$-49.21M |
-12.7% |
| 2019 |
$-3.37 |
$390.26M |
$-103.69M |
-26.6% |
| 2020 |
$-2.47 |
$362.05M |
$-83.07M |
-22.9% |
| 2021 |
$-3.77 |
$386.91M |
$-131.36M |
-34% |
| 2022 |
$0.08 |
$406.37M |
$3M |
0.7% |
| 2023 |
$-2.56 |
$425.17M |
$-92.21M |
-21.7% |
| 2024 |
$-3.06 |
$408.52M |
$-113.44M |
-27.8% |
